NCT Number: NCT04373564
Phase: PHASE4
Trial Summary: This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA. The study aims to create detaile – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Guerbet
Acronym: ODYSSEY
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives